Our in vivo results showed that fasudil administration notably improved peritoneal function and relieved peritoneal fibrosis by decreasing the thickness of the peritoneum, reducing extracellular matrix accumulation, and inhibiting the expression of TGF-β, FN, and α-SMA in the visceral peritoneum. Here, ACTA1 is linked to Peritoneal Fibrosis.